FDA green light sets Nanobiotix up to start nanoparticle prostate cancer trial

Nanobiotix is gearing up for the first U.S.-based clinical trial of its nanoparticle therapy, NBTXR3. Nanobiotix will test NBTXR3 in an open-label Phase I/II trial, in which people with prostate cancer will receive the experimental nanoparticle in conjunction with one of two types of radiotherapy.

Fierce Biotech